MEDCAC Review of PGx Cancer Tests Finds Some Clinical Utility, More Evidentiary Gaps
February 03, 2010
MEDCAC Review of PGx Cancer Tests Finds Some Clinical Utility, More Evidentiary Gaps
Although CMS does not have a national coverage determination on pharmacogenomic testing in cancer, a CMS advisory committee met last week in Baltimore, Md., to discuss whether five tests are clinically useful in the Medicare population.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - Transgenomic Hopes to Attract Pharma Partners with Exclusive License to PIK3CA/PTEN PGx Testing
June 1, 2011 / Pharmacogenomics Reporter - ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter